Somewhat Positive Media Coverage Somewhat Unlikely to Impact Sinovac Biotech (SVA) Stock Price

News headlines about Sinovac Biotech (NASDAQ:SVA) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.3301028445089 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s rankings:

Sinovac Biotech (NASDAQ SVA) traded down 0.15% during mid-day trading on Tuesday, hitting $6.80. The stock had a trading volume of 83,225 shares. The stock’s market cap is $387.38 million. The firm has a 50-day moving average of $6.79 and a 200-day moving average of $6.01. Sinovac Biotech has a 52-week low of $4.60 and a 52-week high of $6.94.

Several analysts have issued reports on the company. BidaskClub raised Sinovac Biotech from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. ValuEngine raised Sinovac Biotech from a “sell” rating to a “hold” rating in a research report on Friday, June 30th.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Insider Buying and Selling by Quarter for Sinovac Biotech (NASDAQ:SVA)

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply